Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Severe Low Anterior Resection Syndrome
NCT06475430Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Live Biotherapeutic Products
01
Overview
Randomised, double-blind trial of allogeneic fecal microbiota in low anterior resection syndrome (LARS) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: bowel function at 8 weeks and Shannon index at 8 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on NCT06475430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475430.